Biogen and Neomorph have entered a research partnership aimed at discovering and developing molecular glue degraders for the treatment of Alzheimer’s disease and other neurological and immunological conditions.

The partnership will leverage Neomorph's molecular glue discovery platform to detect and validate new small molecule therapeutic molecular glue degraders.

Neomorph CEO, co-founder and president Phil Chamberlain stated: "Neomorph's molecular glue degrader platform represents a unique approach to drug discovery.

"We are excited to partner with Biogen, a leader in Alzheimer’s, rare and immunological diseases, to explore the potential of our technology in addressing some of the most challenging and valuable targets in these fields."

The parties will work together to detect, validate and streamline small molecule molecular glue degraders for high-priority targets.

Biogen will be responsible for advancing the clinical candidates for further development and subsequent commercialisation.

Neomorph will receive an upfront payment and milestone payments per target in the future as the deal advances.

These payments include specific near-term pre-clinical milestones and clinical, regulatory, commercial, and sales milestones expected towards the end of the 2020s and beyond, with a potential total of up to $1.45bn.

Neomorph is also eligible for royalty payments on future product sales.

Biogen research head Jane Grogan stated: "As part of our modality agnostic research strategy, Biogen is committed to investing in new approaches to unlock biological targets that have remained difficult to reach.

“This collaboration with Neomorph reflects the approach we want to take to pair our internal drug development expertise with cutting-edge external innovation to create clinically meaningful therapies for patients."

In February 2024, Neomorph signed an agreement with Novo Nordisk for the discovery and development of molecular glue degraders for cardiometabolic and rare diseases.